Abstract
Dendritic cells (DCs) are the key antigen presenting cells that link innate and adaptive immunity. In the periphery, DCs capture antigens, process them and migrate into the regional lymph nodes where they could initiate antigen specific T cell immune responses. Immunotherapeutic strategies that aim to deliver tumor antigens specifically to DCs could not only boost anti-tumor immune responses but also could alleviate non-specific immune activation and/or unwanted side effects. Nano-sized particulate delivery systems are efficient modalities that can deliver tumor antigens to DCs in a targeted and specific manner. This review will provide general information on the rationale behind targeting antigens to DCs and the crucial role of DCs in initiating antigen specific T cell responses. Different strategies that have been employed in delivering antigens to DCs will be also discussed. A special emphasis will be put on specific targeting of cancer vaccine formulations to DC-specific receptors (e.g. CD11c, CD40, Fcγ, CCR6, pathogenic recognition receptors such as Toll-like receptors (TLRs) and C-type lectin receptors (CLRs)).
Keywords: Cancer vaccines, dendritic cells, immunotherapy, nanotechnology, targeting, malignant cells, tumour antigens, tolerogenic DCs, immunostimulators, lymphoid organs, T cell repertoire, dendrites, peptides, viral vectors
Current Drug Delivery
Title: Part I: Targeted Particles for Cancer Immunotherapy
Volume: 8 Issue: 3
Author(s): Samar Hamdy, Azita Haddadi, Zahra Ghotbi, Ryan W. Hung and Afsaneh Lavasanifar
Affiliation:
Keywords: Cancer vaccines, dendritic cells, immunotherapy, nanotechnology, targeting, malignant cells, tumour antigens, tolerogenic DCs, immunostimulators, lymphoid organs, T cell repertoire, dendrites, peptides, viral vectors
Abstract: Dendritic cells (DCs) are the key antigen presenting cells that link innate and adaptive immunity. In the periphery, DCs capture antigens, process them and migrate into the regional lymph nodes where they could initiate antigen specific T cell immune responses. Immunotherapeutic strategies that aim to deliver tumor antigens specifically to DCs could not only boost anti-tumor immune responses but also could alleviate non-specific immune activation and/or unwanted side effects. Nano-sized particulate delivery systems are efficient modalities that can deliver tumor antigens to DCs in a targeted and specific manner. This review will provide general information on the rationale behind targeting antigens to DCs and the crucial role of DCs in initiating antigen specific T cell responses. Different strategies that have been employed in delivering antigens to DCs will be also discussed. A special emphasis will be put on specific targeting of cancer vaccine formulations to DC-specific receptors (e.g. CD11c, CD40, Fcγ, CCR6, pathogenic recognition receptors such as Toll-like receptors (TLRs) and C-type lectin receptors (CLRs)).
Export Options
About this article
Cite this article as:
Hamdy Samar, Haddadi Azita, Ghotbi Zahra, W. Hung Ryan and Lavasanifar Afsaneh, Part I: Targeted Particles for Cancer Immunotherapy, Current Drug Delivery 2011; 8 (3) . https://dx.doi.org/10.2174/156720111795256101
DOI https://dx.doi.org/10.2174/156720111795256101 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sphere Formation Assay is not an Effective Method for Cancer Stem Cell Derivation and Characterization from the Caco-2 Colorectal Cell Line
Current Stem Cell Research & Therapy HIV-1 Infection: Recent Developments in Treatment and Current Management Strategies
Anti-Infective Agents in Medicinal Chemistry Maternal Sepsis: Current Approaches to Recognition and Clinical Management
Current Women`s Health Reviews Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways
Current Molecular Medicine A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets Involvement of Lanthanides in the Free Radicals Homeostasis
Current Topics in Medicinal Chemistry Inorganic Nanoparticles for Enhanced Photodynamic Cancer Therapy
Current Drug Discovery Technologies In Vivo Anticancer Activity, Toxicology and Histopathological Studies of the Thiolate Gold(I) Complex [Au(Spyrimidine)(PTA-CH<sub>2</sub>Ph)]Br
Anti-Cancer Agents in Medicinal Chemistry Calcium-suppressed Technique in Dual-layer Detector Computed Tomography to Evaluate Knee Articular Cartilage
Current Medical Imaging Vitamin Bs, One Carbon Metabolism and Prostate Cancer
Mini-Reviews in Medicinal Chemistry Potential Applications of <i>Sarcopoterium Spinosum</i> as Medicinal Plants: Overview and Future Trends
Current Traditional Medicine Beta-Caryophyllene Suppresses Ovarian Cancer Proliferation by Inducing Cell Cycle Arrest and Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Treatment with Radix Euphorbiae Ebracteolatae Significantly Decreases the Expression of E6 and L1, and Increases the Expression of p53 and Rb in HPV18-infected Human Foreskin Keratinocytes
Current Molecular Medicine An Overview on Pyranocoumarins: Synthesis and Biological Activities
Current Organic Chemistry Heat Shock Proteins as Prognostic Markers of Cancer
Current Cancer Drug Targets γ-H2AX as a Therapeutic Target for Improving the Efficacy of Radiation Therapy
Current Cancer Drug Targets Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway
Current Topics in Medicinal Chemistry Use of Metallomics in Environmental Pollution Assessment Using Mice Mus musculus/Mus spretus as Bioindicators
Current Analytical Chemistry Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
Current Signal Transduction Therapy Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets